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al -Microglobulin (cx1-m) is a highly glycosylated polypeptide of 182 amino acids associated with a brown chromophore (Ekstr6m et al., 1975; Lopez Otin et al., 1984) . The molecule is heterogeneous in charge and was described as HC protein (Tejler & Grubb, 1976) or acl-microglycoprotein (Seon & Pressmann, 1978) . It occurs in biological fluids as a 31 kDa monomer and as a 90kDa component covalently associated to one a chain of monomeric immunoglobulin A (IgA) (Grubb et al., 1983; . The al-m gene is associated with a gene coding for the HI-30 domain of interax-trypsin inhibitor, one of the acute phase proteins (Kaumeyer et al., 1986) . The human 31 kDa al-m was shown to be synthesised by fetal liver explants (Tejler et al., 1978) and we recently reported that the molecule was produced in vitro by several human hepatoma cell lines but not by lymphoma or plasmocytoma cell lines . For these reasons we have determined serum levels of al-m in a large series of patients suffering from primary hepatocellular carcinoma in order to evaluate the possible use of this molecule as an additional tumour marker. The data show that 31 kDa al-m levels are usually not increased in this disease, whereas the 90kDa component levels are elevated in some cases.
Our study involved a hundred South African Blacks with histologically proven hepatocellular carcinoma. They included 11 women and 89 men whose ages ranged from 20 to 73 years (median 39). Seventy-seven healthy South African Black subjects served as controls. All serum samples were sent frozen in dry ice from South Africa and were stored at -40°C until use.
The differential quantitation of 31 kDa and IgA-associated 90 kDa ocl-m in unfractionated sera was performed by a E H enzyme linked immunosorbent assay (ELISA) as previously described . Briefly, the monoclonal antibody 832 ALB which binds both forms of cxl-m with high affinity (1.4 x 1010 L/M) was used as solid phase. The binding of serum a1-m was assessed by addition of polyconal immunopurified biotinylated antibodies specific for cal-m or for the heavy chain of IgA, then by incubation with peroxidase-streptavidin, addition of the substrate and recording of the absorbance at 280nm. Interassay coefficients of variation did not exceed 16%. Normal levels of 31 kDa in 25 French adults were 9.54 + 2.73 mg1 -1 (mean + s.d.). As regards 90 kDa al-m, normal levels in the same control group were 101.9 + 36.6 kU 1 1 .
Albumin concentrations were measured by radial immunodiffusion, #2-microglobulin and IgA by competitive ELISA (Vincent & Revillard, 1986; . axFetoprotein and HBs antigen were determined by solid phase radio-immunoassay, y-glutamyl transpeptidase and alkaline phosphatase activities by routine biochemical methods. The upper limit values for serum 31 kDa and 90 kDa o1-m were defined by the 90th percentile of the control group (Soleberg, 1985) . Comparisons between groups were based on the Mann-Whitney U test. Individual serum levels of 31kDa and 90kDa cx1-m are presented in Figure 1 . In healthy subjects from South Africa serum levels of 31kDa cx1-m were similar to that of European controls whereas those of the 90kDa form appeared to be slightly lower. Twenty-two patients had 31 kDa cl-m levels above the upper limit of control values but the distribution in patients did not differ from that of controls. As regards 90 kDa ox1-m levels, 35 patients had elevated values and the overall distribution differed from that of healthy controls (P<0.002, Mann-Whitney U test). Serum IgA concentrations were elevated in four of the patients and were not correlated with 90 kDa o 1-m levels. No difference in c 1-m levels was found between the 54HBs antigen-positive and HBs antigen-negative patients. The concentrations of serum albumin were not correlated with those of (xi-m.
Finally, oa-fetoprotein was increased in 91% of patients' sera, f2-microglobulin in 59%, alkaline phosphatase activity in 78% and y-glutamyltranspeptidase in 94% but none of these biological parameters was correlated with a1-m levels.
Serum levels of 31 kDa a1-m were reported to rise in renal insufficiency (Itoh et al., 1983; Yu et al., 1983) and in a few patients with malignant tumours, including the only two cases of hepatoma that were investigated (Tagaki et al., 1980) . Immunohistochemical studies of normal human tissues showed that hepatocytes were intensely stained by anti-cx1-m antibodies along with macrophages and some lymphocytes (Bouic et al., 1984) . Studies of human fetal livers revealed that fetal hepatocytes but not haematopoietic stem cells were strongly labelled by anti-a,-m antibodies (Bouic et al., unpublished data) . Furthermore, the protein was shown to be synthesised by human fetal liver explants (Tejler et al., 1978) and produced in high amounts by some human hepatocarcinoma cell lines . Therefore al1-m was considered as a potential biologic marker of hepatocellular carcinoma. However, the present study demonstrates that this prediction was not confirmed, despite the significant elevation of 90 kDa a1-m in the patients group as compared with controls.
